ADAPTIMMUNE THERAPEUTICS PLC's ticker is ADAP and the CUSIP is 00653A107. A total of 78 filers reported holding ADAPTIMMUNE THERAPEUTICS PLC in Q3 2023. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,351,850 | -15.7% | 1,733,141 | -0.0% | 0.00% | – |
| Q2 2023 | $1,603,570 | -53.4% | 1,733,590 | -45.1% | 0.00% | – |
| Q1 2023 | $3,441,746 | +49.3% | 3,157,566 | +100.0% | 0.00% | – |
| Q4 2022 | $2,305,023 | +35.8% | 1,578,783 | 0.0% | 0.00% | – |
| Q3 2022 | $1,697,000 | -36.8% | 1,578,783 | 0.0% | 0.00% | – |
| Q2 2022 | $2,684,000 | -17.5% | 1,578,783 | 0.0% | 0.00% | – |
| Q1 2022 | $3,252,000 | -45.1% | 1,578,783 | 0.0% | 0.00% | – |
| Q4 2021 | $5,920,000 | -27.5% | 1,578,783 | 0.0% | 0.00% | -100.0% |
| Q3 2021 | $8,162,000 | +21.3% | 1,578,783 | -0.0% | 0.00% | 0.0% |
| Q2 2021 | $6,726,000 | -19.8% | 1,578,784 | +0.0% | 0.00% | 0.0% |
| Q1 2021 | $8,383,000 | -1.5% | 1,578,783 | 0.0% | 0.00% | 0.0% |
| Q4 2020 | $8,510,000 | -57.7% | 1,578,783 | -37.4% | 0.00% | -50.0% |
| Q3 2020 | $20,140,000 | -20.3% | 2,523,783 | 0.0% | 0.00% | -33.3% |
| Q2 2020 | $25,263,000 | +488.3% | 2,523,783 | +59.9% | 0.00% | +200.0% |
| Q1 2020 | $4,294,000 | +126.6% | 1,578,783 | 0.0% | 0.00% | – |
| Q4 2019 | $1,895,000 | -20.5% | 1,578,783 | 0.0% | 0.00% | – |
| Q3 2019 | $2,384,000 | -62.4% | 1,578,783 | 0.0% | 0.00% | -100.0% |
| Q2 2019 | $6,347,000 | -6.5% | 1,578,783 | 0.0% | 0.00% | 0.0% |
| Q1 2019 | $6,789,000 | -25.2% | 1,578,783 | 0.0% | 0.00% | 0.0% |
| Q4 2018 | $9,078,000 | -70.2% | 1,578,783 | -29.6% | 0.00% | -66.7% |
| Q3 2018 | $30,426,000 | -25.1% | 2,243,825 | -34.5% | 0.00% | -40.0% |
| Q2 2018 | $40,647,000 | -5.4% | 3,424,373 | -10.5% | 0.01% | 0.0% |
| Q1 2018 | $42,983,000 | +38.9% | 3,827,467 | -17.4% | 0.01% | +25.0% |
| Q4 2017 | $30,937,000 | -24.0% | 4,631,259 | -6.8% | 0.00% | -20.0% |
| Q3 2017 | $40,684,000 | +72.2% | 4,967,550 | -5.6% | 0.01% | +66.7% |
| Q2 2017 | $23,626,000 | -31.7% | 5,261,750 | -16.2% | 0.00% | -25.0% |
| Q1 2017 | $34,612,000 | +21.0% | 6,281,650 | -11.1% | 0.00% | 0.0% |
| Q4 2016 | $28,614,000 | -42.6% | 7,065,180 | 0.0% | 0.00% | -42.9% |
| Q3 2016 | $49,809,000 | -13.5% | 7,065,180 | 0.0% | 0.01% | -12.5% |
| Q2 2016 | $57,581,000 | +0.1% | 7,065,180 | -0.2% | 0.01% | 0.0% |
| Q1 2016 | $57,549,000 | -27.6% | 7,078,480 | +7.4% | 0.01% | -27.3% |
| Q4 2015 | $79,503,000 | +37.8% | 6,592,301 | +36.8% | 0.01% | +37.5% |
| Q3 2015 | $57,695,000 | -49.0% | 4,820,007 | -21.8% | 0.01% | -42.9% |
| Q2 2015 | $113,038,000 | – | 6,166,793 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| MPM ASSET MANAGEMENT LLC | 6,287,101 | $4,903,939 | 2.63% |
| Syncona Portfolio Ltd | 1,377,294 | $1,074,289 | 1.60% |
| MPM BioImpact LLC | 5,095,912 | $3,974,811 | 1.06% |
| NEA Management Company, LLC | 17,079,778 | $13,322,227 | 1.03% |
| TANG CAPITAL MANAGEMENT LLC | 5,166,954 | $4,030,224 | 0.57% |
| PFM Health Sciences, LP | 10,423,135 | $8,130,045 | 0.38% |
| Matrix Capital Management Company, LP | 38,974,185 | $30,399,864 | 0.36% |
| Long Focus Capital Management, LLC | 10,963,158 | $8,551,263 | 0.31% |
| Acuitas Investments, LLC | 479,764 | $374,216 | 0.22% |
| Endurant Capital Management LP | 311,944 | $243,316 | 0.22% |